Immobilized Cynomolgus PSMA, His Tag (Cat. No. PSA-C5247) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human PSMA Antibody, Human IgG1 with a linear range of 0.2-4 ng/mL (QC tested).
The purity of Cynomolgus PSMA, His Tag (Cat. No. PSA-C5247) was more than 85% and around 185-220 kDa verified by SEC-MALS.
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| MBP-K007 | Human | PSMA-coupled magnetic beads | |||
| PSA-H5264 | Human | Human PSMA / FOLH1 Protein, Fc Tag |  |
|
|
| PSA-M5245 | Mouse | Mouse PSMA / FOLH1 Protein, His Tag |  |
|
|
| PSA-C5247 | Cynomolgus | Cynomolgus PSMA / FOLH1 Protein, His Tag (MALS verified) |  |
|
|
| PSA-HF244 | Human | FITC-Labeled Human PSMA / FOLH1 Protein, His Tag |  |
|
|
| PSA-H82Qb | Human | Biotinylated Human PSMA / FOLH1 Protein, His,Avitag™ |  |
|
|
| PSA-H52H3 | Human | Human PSMA / FOLH1 Protein, His Tag (MALS verified) |  |
|
|
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Capromab pendetide | 111In CYT-356; CYT-356; Indium-111-CYT-356; lndium-CYT-356 | Approved | EUSA Pharma | PROSTASCINT | fda | Prostate cancer | CYTOGEN | 1996-10-28 | Prostate cancer, Diagnostic agents | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| MIP-1375 | 131-I-MIP-1375;MIP-1375 | Preclinical | Progenics Pharmaceutical | Prostate cancer | Details |
| CYT-500-Lu-177 | CYT-500-Lu-177; 177LuCYT500 | Phase Ⅰ | Cytogen | Prostate cancer | Details |
| 99mTc-EC-0652 | EC-0652; 99mTc-EC-0652; DUPA-99mTc; EC-0652-99mTc | Phase Ⅰ | Novartis | Prostate cancer | Details |
| INO-5150 | INO-5150 | Phase Ⅰ | Inovio | Prostate cancer | Details |
| INO-5401 | INO-5401; INO5401 | Phase Ⅱ | Inovio | Glioblastoma | Details |
| [131I]MIP-1095 | 1095; [131I]MIP-1466; [131I]MIP-1095 | Phase Ⅱ | Progenics Pharmaceutical | Prostate cancer | Details |
| [18F]DCFPyL | Phase Ⅲ | Johns Hopkins University, Progenics Pharmaceutical, Sidney Kimmel Cancer Center | Prostate cancer, Renal carcinoma | Details | |
| Df-IA2BM-Zr-89 | Df-IA2BM-Zr-89; IAB2M; 89Zr-Df-IAB2M; 64Cu-NODAGA-PSMA-Mb | Phase Ⅱ | ImaginAb | Glioma, Prostate cancer | Details |
| Fluorine-18-CTT-1057 | 18F-CTT1057; CTT-1057; CTT-1057-18F; CTT-1057-F-18 | Phase Ⅰ | Washington University, Cancer Targeted Technology | Renal cell carcinoma | Details |
| P28z-CAR | P28z-CAR | Phase Ⅰ | Memorial Sloan-Kettering Cancer Center, United States Department of Defense | Prostate cancer | Details |
| MDX-070 | MDX-070,MDX-70 | Phase Ⅱ | Northwest Biotherapeutics, Medarex | Prostate cancer | Details |
| MOR-209/ES414 | APVO-414; MOR-209; ES-414 | Phase Ⅰ | Emergent, MorphoSys | Prostate cancer | Details |
| CART-PSMA-TGFbRDN (University of Pennsylvania) | Phase Ⅰ | University of Pennsylvania | Castration-resistant prostate cancer (CRPC) | Details | |
| Technetium Tc 99m trofolastat | 99mTc-MIP1404; F-1311; MIP-1404; MP-1404 | Phase Ⅲ | Progenics Pharmaceutical, FUJIFILM Corporation | Tumor imaging agent | Details |
| Anti-PSMA CAR T-cell therapy (TNK Therapeutics) | Phase Ⅰ | Sorrento Therapeutics | Cancer | Details | |
| 177Lu-capromab pendetide (Cytogen) | CYT-500; 177Lu-7E11.C5.3; 177Lu-CYT-500; 7E11-C5.3-meO- DOTA-177Lu; Anti-PSMA-meO-DOTA-177Lu | Phase Ⅰ | Jazz Pharmaceuticals | Prostate cancer, Cancer | Details |
| 4SCAR-PSMA T cell therapy (Shenzhen Geno-Immune Medical Institute) | Phase Ⅱ | Shenzhen Geno-Immune Medical Institute | Malignancies | Details | |
| Autologous T-cell therapy (anti-PSMA-CD3), Roger Williams Medical Center | Phase Ⅰ | Roger Williams Medical Center | Prostate cancer | Details | |
| Pasotuxizumab | AMG-212; BAY-2010112; MT-112 | Phase Ⅰ | Amgen, Bayer | Prostate cancer | Details |
| 68Ga-PSMA-R2 (Advanced Accelerator Applications SA) | Phase Not Specified | Advanced Accelerator Applications | Prostate cancer | Details | |
| HPN-424 | HPN-424 | Phase Ⅰ | Harpoon Therapeutics | Metastatic castration-resistant prostate cancer (mCRPC) | Details |
| GPI-5693 | GPI-5693 | Phase Ⅰ | Eisai | Neuropathic pain, Diabetic neuropathy, Prostate cancer | Details |
| 177Lu-PSMA-R2 | 177Lu-PSMA-R2; 177Lu-PSMA-SR6 | Phase Ⅱ | Advanced Accelerator Applications | Prostate cancer | Details |
| PSMA-CART cell therapy (Shanghai Bioray Laboratory) | Phase Ⅱ | Shanghai Bioray Laboratory Inc, Changhai Hospital of Shanghai | Castration-resistant prostate cancer (CRPC) | Details | |
| CC-1 | CC-1 | Phase Ⅰ | The University of Tubingen, German cancer research center | Castration-resistant prostate cancer (CRPC) | Details |
| 68Ga-PSMA-617 | 68Ga-PSMA-617; 225 Ac-PSMA-617; PSMA-617-[68Ga]; Gallium-68-PSMA-617; 68Ga-DKFZ-617; 68Ga-DKFZ-PSMA -617; 68Ga-DOTA-PSMA-DKFZ -617 | Phase Not Specified | University of Heidelberg, Deutsches Krebsforschungszentrum | Prostate cancer | Details |
| ATL-101 (ATLAB) | 177Lu-J591; 90Y-J591; huJ-591; J-591; Lu-177-J591; MLN-591RL; MLN-591; muJ-591 | Phase Ⅱ | Cornell University, Weill Cornell Medical College, BZL Biologics | Prostate cancer | Details |
| 89Zr-DFO-huJ591 | 89Zr-DFO-J591; 89Zr-DFO-huJ591; Zr89-J591,89Zr DFO J591; 89Zr DFO huJ591; Zr89 J591 | Phase Ⅱ | Memorial Sloan-Kettering Cancer Center | Prostate cancer | Details |
| PSMA ADC | PSMA-ADC | Phase Ⅱ | Progenics Pharmaceutical, PSMA Development Company, Brown University, Rhode Island Hospital, University of Texas at Dallas | Prostate cancer, Glioblastoma | Details |
| ATL-101 | ATL-101; TLX-591 | Phase Ⅱ | Telix Pharmaceuticals, Weill Cornell Medical College, BZL Biologics | Prostate cancer | Details |
This web search service is supported by Google Inc.
A-Z